Precision Medicine

Multidisciplinary Tumor Board: Focus on Early-Stage KRAS Mutated NSCLC

Brendon Stiles, MD; Charu Aggarwal, MD, MPH
An Update on the role of ctDNA-MRD Assessment in The Management of Breast Cancer

Jason A. Mouabbi, MD
NSCLC: The Evolving Landscape of KRAS G12C Therapy

Timothy F. Burns, MD, PhD; Charu Aggarwal, MD, MPH
Current and Evolving Approaches for HER2+ Breast Cancer Brain Metastases

Carey Anders, MD
Management of HER2+ Breast Cancer Brain Metastases

Sarah Sammons, MD
The Evolving Roles of Neoadjuvant and Adjuvant Therapy in EGFRm NSCLC

Tina Cascone, MD, PhD
Importance of NGS testing for STK11 and KEAP1 mutation and impact on treatment selection

Charu Aggarwal, MD, MPH, Biagio Ricciuti, MD, PhD
Early Stage NSCLC – EGFR Mutant NSCLC

Charu Aggarwal, MD, MPH
Advances in The Management of Early-Stage EGFRm NSCLC

Charu Aggarwal, MD, MPH
The Evolving Approach to Management of Stage IV EGFRm NSCLC

Charu Aggarwal, MD, MPH
Advances in the Management of Colorectal Cancer: Recent Evidence and Emerging Treatment Paradigms

John Strickler, MD
Evolving Treatment Landscape for HER2 Positive Gastroesophageal Adenocarcinoma

John Strickler, MD